iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that researchers from Hospital Universitario Miguel Servet in Zaragoza, Spain will present new results from three clinical studies supporting the efficacy of the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer and gynecological cancers during the European Society for Radiotherapy & Oncology (ESTRO 37) meeting at the Barcelona International Convention Centre in Barcelona, Spain. The Xoft System is a proprietary eBx platform designed to deliver isotope-free (non-radioactive) radiation therapy.
"We are pleased that clinical results from multiple studies continue to demonstrate the therapeutic value of this innovative treatment option," said Ken Ferry, CEO of iCAD. "This important new research adds to a growing body of data confirming the significant benefits that the Xoft System offers to patients and clinicians worldwide."
At ESTRO 37, clinicians from Hospital Universitario Miguel Servet will present new preliminary findings from three studies that further demonstrate the efficacy of the Xoft System in the treatment of early-stage breast cancer and gynecological cancers. Since their adoption of the technology in 2015, clinicians at Hospital Universitario Miguel Servet have treated more than 350 early-stage breast cancer and gynecological cancer patients with the Xoft System.
Ad Statistics
Times Displayed: 22487
Times Visited: 455 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
"By precisely targeting cancer cells and sparing surrounding healthy tissue, the Xoft System has empowered our clinicians to significantly improve patient outcomes and reduce toxicity in treating a range of cancers," said Martin Tejedor, M.D., Chief of Radiation Oncology, Hospital Universitario Miguel Servet. "We are very encouraged by our results to date with this transformative technology, and we are committed to offering this valuable treatment option to appropriately selected patients in Spain."
Summarized findings and links to the electronic data are available below.
PO-1089: IORT for Breast Cancer Treated with Axxent Xoft. Our Experience: Toxicity Analysis
Preliminary results in 136 patients treated from May 2015 to August 2016 show feasible acute and late toxicity and good cosmetic outcomes.
EP-1314: Breast Treatments with Axxent Equipment. Comparison with Mammosite for Skin, Lung and Heart Dose
